Research report
Therapeutic efficacy of antidepressants in agitated anxious depression — a meta-analysis of moclobemide studies

https://doi.org/10.1016/0165-0327(95)00034-KGet rights and content

Abstract

The results of the meta-analysis of studies comparing the efficacy of moclobemide, imipramine and so-called sedative antidepressants (amitriptyline, mianserin and maprotiline) in 2416 patients are described. The results demonstrated that in agitated-anxious depressive patients (defined by HAMD factor score or HAMD item 9) a nonsedative, reversible MAO-A inhibitor moclobemide has about equal efficacy as imipramine or sedative antidepressants. All antidepressants were clearly superior to placebo, irrespective of the outcome measures applied (> 50% HAMD decrease, CGI improvement). The efficacy of antidepressants in agitated patients was unrelated to the severity of agitation and did not appear to be inferior to the efficacy in nonagitated patients. Comedication with benzodiazepines had no impact on overall efficacy of either moclobemide or other antidepressants in this patient population. Previous treatment with antidepressants, however, always negatively influenced the outcome with trial drugs, e.g., reduced their efficacy. Placebo response in agitated depressives appeared generally to be low (20–30%) and was clearly reduced with increased severity of agitation, irrespectively of how the agitation was defined.

References (24)

  • J. Angst

    Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials. A meta-analysis of moclobemide trials

    Human Psychopharmacol.

    (1993)
  • J. Angst et al.

    Moclobemide in special sub-groups of depression

    Rev. Contemp. Pharmacother.

    (1994)
  • J. Angst et al.

    Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton depression rating scale

    Clin. Neuropharmacol.

    (1993)
  • J. Angst et al.

    Efficacy of moclobemide in different patient groups: a meta-analysis of studies

    Psychopharmacology

    (1992)
  • D. Baldwin et al.

    Tolerability of moclobemide

    Rev. Contemp. Pharmacother.

    (1994)
  • C.M. Beasley et al.

    High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression

    J. Clin. Psychopharmacol.

    (1991)
  • O. Benkert et al.

    Psychiatrische Pharmakotherapie

    (1980)
  • M. Da Prada et al.

    Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors

    J. Neural Transm.

    (1989)
  • M. Da Prada et al.

    The pharmacology of moclobemide

    Rev. Contemp. Pharmacother.

    (1994)
  • A. Delini-Stula

    Pharmakologie der Antidepressiva

  • A. Delini-Stula

    Grundlegendes zur Antidepressivatherapie

  • F.A. Freyhan

    The modern treatment of depressive disorder

    Am. J. Psychiatry

    (1960)
  • Cited by (48)

    • Identification and management of anxious depression in patients with treatment-resistant depression

      2022, Managing Treatment-Resistant Depression: Road to Novel Therapeutics
    • Studies on the sonochemical polymorphism of Sb<inf>2</inf>O<inf>3</inf> on activated graphite for the electrochemical determination of imipramine

      2020, Ultrasonics Sonochemistry
      Citation Excerpt :

      The effect of phases and graphite in the aGR-Sb2O3 has investigated in the electroanalytical studies of anti-depressant drug imipramine (IMP). IMP is a tricyclic antidepressant drug mostly prescribed for the treatment of depression, and sometimes bed-wetting and anxiety [11]. Also, IMP has been used as a muscle relaxant and pain reliever for patients who have chronic pain associated with autoimmune diseases such as rheumatoid arthritis [12,13].

    • Other therapeutic strategies

      2016, Presse Medicale
    • New insights into the neurobiological mechanisms of major depressive disorders

      2015, General Hospital Psychiatry
      Citation Excerpt :

      Nowadays, many treatments rely on the use of selective neurotransmitter reuptake inhibitors in order to improve the symptoms of patients affected with MDD. For instance, the tricyclic antidepressant (TCA) drug imipramine is often used for the treatment of MDD [45,46]. It acts by inhibiting the reuptake of the noradrenaline by the presynaptic cell.

    • Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase

      2015, Toxicology Letters
      Citation Excerpt :

      The reversible AChE-ligands, most of them having effective medical applications in various neurological disorders, were found to inhibit human AChE at different concentrations. This result is in agreement with previous results generated with AChE from different species (Delini-Stula et al., 1995; Iwanaga et al., 1994; Lockhart et al., 2000; Loewenick et al., 2001; Woltjer and Milatovic, 2006; Zeldowicz and Buckler, 1965). Donepezil was the most potent reversible AChE-inhibitor in the series of compounds tested as summarized in Table 1.

    • Intra-lateral septal infusions of folic acid alone or combined with various antidepressant drugs produce antidepressant-like actions in male Wistar rats forced to swim

      2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry
      Citation Excerpt :

      However, the open field test can be used as an animal model of anxiety (Treit and Fundytus, 1988). Many researchers use it as a complement to the FST to avoid false positive results that can be obtained in the FST, since some antidepressant drugs may also produce sedative effects (Delini-Stula et al., 1995), as fluoxetine or desipramine did. In the present study, we performed the open field test before the test session in the FST, so a possible criticism of our data is that stress from the open field test might affect the results of the FST.

    View all citing articles on Scopus
    View full text